BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne’s extensive global innovation pipeline and platforms, including new assets, targets and clinical data, and will share in...

Philip Morris International Inc. (NYSE: PM) today issues an urgent call for effective policymaking to counter the growing threat of illicit trade in the EU. In 2024, 38.9 billion illicit cigarettes were consumed in the region—the highest level since 2015—accounting for 9.2% of total cigarette consumption, with governments losing as much as €14.9 billion in tax revenues at a time when many countries face intense economic pressures. PMI believes that exacerbating the issue are steep and abrupt ...

Hansen Technologies (ASX:HSN), a global provider of software and services to the communications, media, energy, and utilities industries, is pleased to announce today that its transformation partnership with Telefónica Germany, a leading communications services providers (CSPs) in Germany, is progressing successfully. In a collaborative effort of more than 3,700 team members, millions of subscribers have already been migrated to a new technology stack, underpinned by products from the Hansen Su...

AngloGold Ashanti plc ("AngloGold Ashanti" or the "Company") has been named for the first time as a preliminary addition to the Russell 1000® or Russell 2000®, the Russell 3000®, and the Russell Midcap® Indexes, as part of the latest FTSE Russell 2025 U.S. Indexes reconstitution. Final index membership will become effective after the U.S. market closes on Friday, 27 June 2025, with rebalanced index constituents reflected in trading beginning Monday, 30 June 2025. “This is an important miles...

TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms ...